Oscar Health Inc (OSCR) PT Raised to $28 at Piper Sandler

Piper Sandler analyst Jessica Tassan raised the price target on Oscar Health Inc (NYSE: OSCR) to $28.00 (from $25.00) while maintaining a Overweight rating.

The analyst commented, "OSCR delivered a consummate 2Q24 beat; with results exceeding PSC/ consensus estimates across all measures of growth and profitability. Spurred by the 1H24 momentum, OSCR raised CY24 revenue guidance by 8.4% at the midpoint and CY24 adjusted EBITDA guidance by 23.3% at the midpoint. Reiterate OW, PT to $28 (prior $25) on an unchanged 15x multiple of higher CY25E adjusted EBITDA."

You May Also Be Interested In

• Calumet Specialty Products Partners (CLMT) PT Raised to $47 at UBS
• Evercore ISI Reiterates Outperform Rating on Apple (AAPL)
• Morgan Stanley Stays Positive on Kanzhun Ltd. (BZ)